Leu-Leu

Leu-Leu

SCHEMBL6044006

CC(C)CC(N)C(=O)N[C@@H](CC(C)C)C(=O)O

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.60
MAPT P10636 1/20 0.58
SLC7A5 Q01650 1/20 0.57
MEN1 O00255 1/20 0.56
LMNA P02545 1/20 0.56
KMT2A Q03164 1/20 0.56
LAP3 P28838 3/20 0.56
FOLH1 Q04609 2/20 0.50
LTA4H P09960 1/20 0.50
MME P08473 4/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Leu-Leu SCHEMBL235249 1.00 ALDH1A1 (0.60) ALDH1A1MAPTSLC7A5MEN1LMNA
Leu-Leu SCHEMBL11140120 1.00 ALDH1A1 (0.60) ALDH1A1MAPTSLC7A5MEN1LMNA
Leu-Leu SCHEMBL29401942 1.00 ALDH1A1 (0.60) ALDH1A1MAPTSLC7A5MEN1LMNA
Leu-Leu SCHEMBL18774992 1.00 ALDH1A1 (0.60) ALDH1A1MAPTSLC7A5MEN1LMNA
Leu-Leu SCHEMBL235250 1.00 ALDH1A1 (0.60) ALDH1A1MAPTSLC7A5MEN1LMNA
Leu-Leu SCHEMBL13737576 1.00 ALDH1A1 (0.60) ALDH1A1MAPTSLC7A5MEN1LMNA
Leu-Leu SCHEMBL30771444 0.98 ALDH1A1 (0.58) ALDH1A1MAPTSLC7A5MEN1LMNA
Leu-Leu SCHEMBL29400696 0.98 ALDH1A1 (0.58) ALDH1A1MAPTSLC7A5MEN1LMNA
SCHEMBL2722888 0.96 ALDH1A1 (0.56) ALDH1A1MAPTSLC7A5MEN1LMNA
SCHEMBL1019805 0.96 ALDH1A1 (0.56) ALDH1A1MAPTSLC7A5MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119224161-A Method for detecting various dipeptides in rumen fluid of ruminant 中国科学院亚热带农业生态研究所 2024-12-31 CN claimed
EP-0460065-B1 A PROCESS FOR THE GENERATION OF PROLIFERATING CD4 LYMPHOCYTES TERUMO CORP (JP) 1994-08-31 EP claimed
US-20060083685-A1 Opioid metallopeptide compositions and methods PALATIN TECHNOLOGIES, INC. (US) 2006-04-20 US disclosed
US-6979436-B2 Opioid metallopeptide compositions and methods PALATIN TECHNOLOGIES, INC. (US) 2005-12-27 US disclosed
US-20050181447-A1 OPIOID METALLOPEPTIDE COMPOSITIONS AND METHODS PALATIN TECHNOLOGIES, INC. 2005-08-18 US disclosed
WO-2001036006-A1 OPIOID METALLOPEPTIDE COMPOSITIONS AND METHODS PALATIN TECHNOLOGIES, INC. (US) 2001-05-25 WO disclosed
US-5919897-A NOVEL OPIOID PEPTIDES TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) 1999-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050181447-A1 OPIOID METALLOPEPTIDE COMPOSITIONS AND METHODS OPRM1, OPRL1, OPRK1 ALDH1A1 3643/4885MAPT 1397/4885SLC7A5 2036/4885
US-20060083685-A1 Opioid metallopeptide compositions and methods OPRM1, OPRL1, OPRK1 ALDH1A1 3635/4885MAPT 1451/4885SLC7A5 2103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.